Computational Identification of Immune- and Ferroptosis-Related LncRNA Signature for Prognosis of Hepatocellular Carcinoma

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2021 Dec 13

PMID 34901153

Citations 6

Authors

Anmin Huang

Ting Li

Xueting Xie

Jinglin Xia

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs), which were implicated in many pathophysiological processes including cancer, were frequently dysregulated in hepatocellular carcinoma (HCC). Studies have demonstrated that ferroptosis and immunity can regulate the biological behaviors of tumors. Therefore, biomarkers that combined ferroptosis, immunity, and lncRNA can be a promising candidate bioindicator in clinical therapy of cancers. Many bioinformatics methods, including Pearson correlation analysis, univariate Cox proportional hazard regression analysis, least absolute shrinkage and selection operator (LASSO) analysis, and multivariate Cox proportional hazard regression analysis were applied to develop a prognostic risk signature of immune- and ferroptosis-related lncRNA (IFLSig). Finally, eight immune- and ferroptosis-related lncRNAs (IFLncRNA) were identified to develop and IFLSig of HCC patients. We found the prognosis of patients with high IFLSig will be worse, while the prognosis of patients with low IFLSig will be better. The results provide an efficient method of uniting critical clinical information with immunological characteristics, enabling estimation of the overall survival (OS). Such an integrative prognostic model with high predictive power would have a notable impact and utility in prognosis prediction and individualized treatment strategies.

Citing Articles

Analysis of expression characteristics of ferroptosis-related lncRNAs in gastrointestinal cancer patients in Asia.

Ding N, Kang Y, Tan X, Tang Y, Zhang Y, He Y Discov Oncol. 2025; 16(1):306.

PMID: 40072763 PMC: 11904047. DOI: 10.1007/s12672-024-01733-3.

Ferroptosis and hepatocellular carcinoma: the emerging role of lncRNAs.

Chen H, Han Z, Su J, Song X, Ma Q, Lin Y Front Immunol. 2024; 15:1424954.

PMID: 38846953 PMC: 11153672. DOI: 10.3389/fimmu.2024.1424954.

Zhu H, Mao F, Wang K, Feng J, Cheng S Front Genet. 2022; 13:972212.

PMID: 36212138 PMC: 9538148. DOI: 10.3389/fgene.2022.972212.

A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma.

Lian J, Zhang C, Lu H Comput Math Methods Med. 2022; 2022:6284540.

PMID: 36035299 PMC: 9410853. DOI: 10.1155/2022/6284540.

A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma.

Zhang G, Sun J, Zhang X Sci Rep. 2022; 12(1):11325.

PMID: 35790864 PMC: 9256635. DOI: 10.1038/s41598-022-15251-1.

References

Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner D . The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019; 68(4):599-608. PMC: 6662600. DOI: 10.1007/s00262-019-02299-8. View

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

Ohue Y, Nishikawa H . Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 2019; 110(7):2080-2089. PMC: 6609813. DOI: 10.1111/cas.14069. View

Barry A, Baldeosingh R, Lamm R, Patel K, Zhang K, Dominguez D . Hepatic Stellate Cells and Hepatocarcinogenesis. Front Cell Dev Biol. 2020; 8:709. PMC: 7419619. DOI: 10.3389/fcell.2020.00709. View

Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M . Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Crit Rev Oncol Hematol. 2020; 157:103167. DOI: 10.1016/j.critrevonc.2020.103167. View

Sun J, Zhang Z, Bao S, Yan C, Hou P, Wu N . Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020; 8(1). PMC: 7057423. DOI: 10.1136/jitc-2019-000110. View

Lou Y, Yu Y, Xu X, Zhou S, Shen H, Fan T . Long non-coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma. J Cell Mol Med. 2018; 23(3):1873-1884. PMC: 6378214. DOI: 10.1111/jcmm.14088. View

Ding B, Lou W, Xu L, Fan W . Non-coding RNA in drug resistance of hepatocellular carcinoma. Biosci Rep. 2018; 38(5). PMC: 6177555. DOI: 10.1042/BSR20180915. View

Pan W, Li W, Zhao J, Huang Z, Zhao J, Chen S . lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. Mol Oncol. 2019; 13(10):2246-2258. PMC: 6763783. DOI: 10.1002/1878-0261.12553. View

10.

Ou Y, Wang S, Li D, Chu B, Gu W . Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci U S A. 2016; 113(44):E6806-E6812. PMC: 5098629. DOI: 10.1073/pnas.1607152113. View

11.

Peng L, Chen Y, Ou Q, Wang X, Tang N . LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma. Int Immunopharmacol. 2020; 89(Pt A):107071. DOI: 10.1016/j.intimp.2020.107071. View

12.

Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J . Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa047. View

13.

Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q . PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020; 11(11):955. PMC: 7648632. DOI: 10.1038/s41419-020-03140-2. View

14.

He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H . Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020; 39(1):159. PMC: 7427719. DOI: 10.1186/s13046-020-01664-1. View

15.

Guo T, Gong C, Wu P, Battaglia-Hsu S, Feng J, Liu P . LINC00662 promotes hepatocellular carcinoma progression via altering genomic methylation profiles. Cell Death Differ. 2020; 27(7):2191-2205. PMC: 7308394. DOI: 10.1038/s41418-020-0494-3. View

16.

Modarresi F, Faghihi M, Lopez-Toledano M, Pedram Fatemi R, Magistri M, Brothers S . Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol. 2012; 30(5):453-9. PMC: 4144683. DOI: 10.1038/nbt.2158. View

17.

Xu H, Ye D, Ren M, Zhang H, Bi F . Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends Mol Med. 2021; 27(9):856-867. DOI: 10.1016/j.molmed.2021.06.014. View

18.

Gong D, Feng P, Ke X, Kuang H, Pan L, Ye Q . Silencing Long Non-coding RNA LINC01224 Inhibits Hepatocellular Carcinoma Progression via MicroRNA-330-5p-Induced Inhibition of CHEK1. Mol Ther Nucleic Acids. 2020; 19:482-497. PMC: 6948252. DOI: 10.1016/j.omtn.2019.10.007. View

19.

Jiang X, Stockwell B, Conrad M . Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282. PMC: 8142022. DOI: 10.1038/s41580-020-00324-8. View

20.

Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J . Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020; 13(1):110. PMC: 7418434. DOI: 10.1186/s13045-020-00946-7. View